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REVIEW
Abstract: Selective serotonin reuptake inhibitors (SSRIs) can safely and successfully treat
major depression, although a substantial number of patients benefit only partially or not at all
from treatment. Genetic polymorphisms may play a major role in determining the response to
SSRI treatment. Nonetheless, it is likely that efficacy is determined by multiple genes, with
individual genetic polymorphisms having a limited effect size. Initial studies have identified
the promoter polymorphism in the gene coding for the serotonin reuptake transporter as
moderating efficacy for several SSRIs. The goal of this review is to suggest additional plausible
polymorphisms that may be involved in antidepressant efficacy. These include genes affecting
intracellular transductional cascades; neuronal growth factors; stress-related hormones, such
as corticotropin-releasing hormone and glucocorticoid receptors; ion channels and synaptic
efficacy; and adaptations of monoaminergic pathways. Association analyses to examine these
candidate genes may facilitate identification of patients for targeted alternative therapies.
Determining which genes are involved may also assist in identifying future, novel treatments.
Keywords: pharmacogenetic, pharmacogenomic, depression, SSRI
Introduction
Major depressive disorder (MDD) is a complex disorder associated with various
monoaminergic disturbances, abnormalities of endocrine regulation, alterations in
sleep physiology, neuroanatomic abnormalities, and neurophysiologic changes
(Drevets 1998; Thase 1998; Manji et al 2001; Ordway et al 2002; Moretti et al 2003;
Sheline 2003; Buysse 2004). Selective serotonin reuptake inhibitors (SSRIs) are
frequently used to treat MDD; however, it is now clear that a large percentage of
patients suffering from MDD may not benefit from SSRI treatment (Thase 2003).
Evidence from family studies indicates that response to specific antidepressant
treatments can be affected by genetic differences (Pare and Mack 1971; O’Reilly et
al 1994; Serretti et al 1998). Pharmacogenetics holds the potential to genetically
predict who will and will not benefit from SSRIs (Catalano 1999; Pickar and Rubinow
2001; Serretti et al 2002). Moreover, delineating the genes that are associated with
poor response to an SSRI may be valuable in identifying alternative patient-specific
treatments, such as novel treatments or currently known and available therapies.
Until recently, the focus of pharmacogenetics has been on functional gene variants
that may contribute to variable antidepressant exposure (ie, pharmacokinetics).
Extensive information is now available regarding genetic variation in many important
metabolic enzymes (for reviews see Brosen 1993; Cohen and De Vane 1996; Steimer
et al 2001; Daly 2003; Evans and McLeod 2003; Mancama and Kerwin 2003). This
review will primarily focus on the putative central mechanisms of SSRI activity and
what is known about genetic variants that moderate those pathways. It will also discuss
the selection of candidate genes based on these pathways. An extensive critique of
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of patients and family members who are treated similarly
for depression and who are assessed using similar outcome
measures (Kopnisky et al 2002; van den Bree and Owen
2003): something that is exceedingly rare.
Population-based association analyses test for associa-
tions of causal candidate polymorphisms or candidate
polymorphisms that are tightly linked to a casual poly-
morphism. Subjects do not need to be genetically related.
However, given that there may be over 30 000 genes and
several million polymorphisms in humans (Sachidanandam
et al 2001; Venter et al 2001; Botstein and Risch 2003),
densely screening the genome may require testing up to a
million polymorphisms per individual (Botstein and Risch
2003). Thus, rather than screen the genome, it is currently
more feasible to select a set of specific candidate genes for
study. Many of these genes may interact in complex ways
to affect treatment response: synergistically, antagonistically,
and additively (Murphy et al 2003). Therefore, a targeted
Table 1 Strategies for selecting candidate genes for
antidepressant response
Enzymes and transporters affecting pharmacokinetics and disposition
Potential mechanism of antidepressant action (proximally and
downstream)
Candidate genes for major depression and mood disorders
Candidate loci from linkage studies in animal models
Expression studies (mRNA and protein) to identify antidepressant-
related genes
Confirm preliminarily identified candidate genes
individual studies will not be provided, but attention will
be given to highlighting the range of potential candidate
genes that can be culled using this strategy.
Linkage analysis in humans to identify the genetic loci
that affect treatment response has been impractical.
Consequently, association analyses are essential (Tabor et
al 2002). Linkage analysis does not require preselection of
candidate genes, but it does require examining several sets
Table 2 Candidate loci with preliminary evidence for involvement in affective disorders based on association analyses
Gene General function Candidate polymorphisms Chromosome allocation
SLC6A4 5-HT reuptake Promoter variable repeat
a 17q11.1-q12
TPH1 5-HT synthesis A218Cb 11p15.3-p14
MAOA 5-HT catabolism Promoter variable repeat
b Xp11.4-911.3
MTHFR Monoamine  synthesis C677T 1p36.3
HTR1A 5-HT receptor C(–1019)G 5q11.2-q13
HTR1B 5-HT receptor C861G 6q13
A(–161)T
HTR2A 5-HT receptor G(–1438)A 13q14-q21
C102T
b
HTR2C 5-HT receptor C(–759)T Xq24
HTR3A 5-HT receptor C178T 11q23.1
HTR6 5-HT receptor C267T 1p36-p35
GNAS1 G-protein subunit – alpha T131C 20q13.2-q13.3
GNB3 G-protein subunit – beta C825Tb 12p13
PLA2 Phospholipase A2 Trinucleotide repeat 1p36.13
BDNF Neuronal growth factor A758G 11p13
NOS1 Neuronal nitric oxide synthesis C29Tb 12q24.2-q24.31
CRH Corticotropin-releasing hormone  T1273C 8q13
CRHR2 CRH receptor G1047A 7p15.1
SLC6A3 Dopamine transporter Promoter variable repeat 5p15.3
SLC6A2 Norepinephrine transporter Promoter variable repeat 16q12.2
ADRB1 Norepinephrine beta 1 receptor G145A 10q24-q26
G1165C
ADRA2A Norepinephrine alpha 2 receptor C(–1291)G 10q24.q26
COMT Monoamine metabolism G158A 22q11.21-q11.23
DRD2 Dopamine 2 receptor –141C insertion/deletion 11q23
CHRM2 Muscarinic 2 receptor A1890T 7q31-q35
APOE Apolipoprotein E C3937T
b 19q13.2
C4075Tb
a Multiple studies replicate an association with SSRI treatment response.
b Polymorphism has a potential preliminary association with antidepressant treatment response in previous studies.
See text for citations. Gene nomenclature is according to HGNC (www.gene.ucl.ac.uk/nomenclature).Neuropsychiatric Disease and Treatment 2005:1(1) 19
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and focused approach for selecting multiple candidate genes
for association analyses is essential.
Several strategies exist for selecting candidate genes for
study (see Table 1). One is to focus on mechanisms of action.
For example, it is now well established that SSRIs inhibit
the serotonin transporter (SERT), acutely increasing
serotonin (5-HT) within the synapse. 5-HT then binds to
several receptors, triggering subsequent intracellular
signaling events through G-proteins (Shelton 2000). Genetic
differences influencing any of these initial and intracellular
signaling events may alter the efficacy of SSRI treatment
(Figure 1). A related strategy focuses on putative
downstream effects of SSRIs, such as alterations in growth
factors and synaptic remodeling, and the effects on synaptic
transmission, other transmitter systems, and/or gluco-
corticoids and corticotropin-releasing hormone (CRH).
Another strategy is to identify genes potentially involved
in the pathophysiology of major depression and related
mood disorders such as bipolar depression (Table 2).
Although the genes affecting treatment response are not
necessarily the same as those increasing vulnerability to
various types of depression, they are biologically plausible
targets for investigation.
Genetic studies using rodent models of depression are
capable of identifying novel candidate genes. For example,
the linkage of antidepressant response to various chromo-
somal regions can be examined in selectively bred and
recombinant inbred lines of mice. Candidate genes may be
selected from these chromosomal regions; a strategy that is
being employed for genes affecting sensitivity to drugs of
abuse (Buck 1995; Phillips 1997; Fehr et al 2002). Similarly,
pharmacogenomic and pharmacoproteomic studies in which
Figure 1 Potential cascade of events mediating and moderating SSRI effects. The multiple inter-regulatory and feedback pathways are absent from this figure.
Abbreviations: BDNF, brain-derived neurotrophic factor; COMT, catecholamine-O-methyl-transferase; CRH, corticotropin-releasing hormone; CRH2, CRH
receptor2; cAMP, cyclic adenosine monophosphate; CREB, cAMP response element binding protein; DARPP-32, dopamine and cAMP regulated phosphoprotein;
DAT, dopamine transporter; MAOA, monoamine oxidase A; NOS, nitric oxide synthase; NET, norepinephrine transporter; 5-HT, serotonin; SERT, serotonin transporter;
SSRI, selective serotonin reuptake inhibitor; TPH, tryptophan hydroxylase.
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the expression levels of genes (either measuring mRNA or
the protein itself) are evaluated following SSRI treatment,
may be useful in identifying novel genes that are important
in mediating SSRI effects (Yamada et al 2000; Landgrebe
et al 2002).
This review will highlight candidate genes that are
selected based on known or prominently postulated
mechanisms of SSRI action, including the initial effects on
synaptic serotonin, intracellular events, and the downstream
effects on growth factors and other neurotransmitter systems
(Figure 1). Supplementary evidence for the involvement of
genes or polymorphisms (Table 2) in depression and related
mood disorders will also be noted.
5-HT transporter and 5-HT
availability
Several proteins and the genes that encode them affect the
initial pathways of SSRI action. A polymorphism in the
upstream regulatory site for the SERT gene (SLC6A4) has
been widely studied. This SERT polymorphism (serotonin
transporter linked polymorphic region; 5-HTTLPR) involves
the presence or absence of a 44 base-pair segment, which
produces a long (L) or short (S) allele; a difference that can
influence transcriptional activity (Heils et al 1997; Lesch
1998). 5-HTTLPR has been associated with susceptibility
to depression (Caspi et al 2003), although there is
considerable heterogeneity between studies (Lotrich et al
2001; Lotrich and Pollock 2004).
The S allele has also been associated with diminished
response to several SSRIs as compared with the L allele in
multiple studies (Arias et al 2000; Pollock et al 2000; Zanardi
et al 2000; Rausch, Johnson, et al 2002; Yu et al 2002; Arias
et al 2003), with two exceptions in Asian populations (Kim
et al 2000; Yoshida, Iko, et al 2002). The S allele may also
increase vulnerability to SSRI side effects (Mundo et al
2001; Murphy GM et al 2003b). While the general finding
of worse outcome in SSRI-treated patients with the S allele
has been well replicated, discrepant reporting in several of
these studies makes it difficult to determine the effect size
of this polymorphism. Among issues to be further clarified
is the effect of 5-HTTLPR in different ethnic populations;
linkage disequilibrium with other polymorphisms in
different ethnic populations; the effect size in different age
groups and at different doses of SSRIs; delineating which
depressive symptoms and side effects are influenced; and
determining how this polymorphism interacts with other
polymorphisms. Moreover, the role of other SLC6A4
polymorphisms remains comparatively unexamined (Lesch
1998; Battersby et al 1999; Michaelovsky et al 1999;
Nakamura et al 2000; Ito et al 2002).
In addition to SERT, monoamine oxidase A (MAOA),
although not typically expressed in 5-HT neurons, also
affects 5-HT levels (Saura et al 1996; Richards et al 1998).
A functional polymorphism in the upstream regulatory
region for MAOA (Sabol et al 1998) can influence response
to SSRIs (Yoshida, Naito et al 2002; Yoshida et al 2003).
As with 5-HTTLPR, the frequency and effect size may differ
among ethnic groups (Yoshida, Naito et al 2002).
Monoamine oxidase B (MAOB) is present in 5-HT neurons
but is less effective in metabolizing 5-HT than MAOA (Saura
et al 1996; Richards et al 1998). MAOB polymorphisms
(Balciuniene et al 2002) have been examined for associations
with Parkinson’s disease, but we are unaware of any
published studies examining a role in affecting SSRI
response.
Tryptophan hydroxylase (TPH) is the rate-limited
enzyme in 5-HT synthesis. A single nucleotide polymorph-
ism (SNP), A218C, may be part of a GATA transcription
factor binding site, and has been associated with suicidal
behavior in Caucasians (Rujescu et al 2003). Initial reports
associated this polymorphism with the rate of response to
SSRIs (Serretti et al 2001a; Serretti, Zanardi, Rossini, et al
2001), although this was not replicated in a smaller study
with Japanese subjects (Yoshida, Naito, et al 2002). A second
gene coding for tryptophan hydroxylase has been identified;
however, whether it is expressed in the human brain remains
controversial (Patel et al 2004). An additional enzyme,
methylenetetrahydrofolate reductase (MTHFR), is involved
in monoamine synthesis, and an MTHFR polymorphism
(C677T) has been associated with major depression
(Bjelland et al 2003).
There are also a number of pathways indirectly
regulating synaptic 5-HT by influencing SERT. For example,
protein kinase C (PKC) activation can decrease SERT
activity (Qian et al 1997; Ramamoorthy et al 1998).
Conversely, SERT co-exists in a complex with protein
phosphatase 2A (PP2A), and dephosphorylation by PP2A
can increase transporter activity at the cell surface (Bauman
et al 2000). Phosphorylation by calcium/calmodulin-
dependent protein kinase II (CAMKII) may also enhance
SERT activity (Yura et al 1996), as can various tyrosine
kinases (Helmeste and Tang 1995). Moreover, transcription
of the SERT gene may be affected by both PKC and protein
kinase A (PKA) (Mossner et al 2000). Interestingly, givenNeuropsychiatric Disease and Treatment 2005:1(1) 21
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that the half-life of SERT is about 3 to 4 days (Vicentic et al
1999), a new steady-state in SERT levels would take about
2 weeks.
Serotonin receptors
At least 14 genes coding for 5-HT receptors are known,
although post-transcriptional processing can result in over
30 5-HT receptor subtypes (Raymond et al 2001). Genetic
differences in receptor number (Bmax), binding (Kd),
kinetics (Vmax and Km), and desensitization rates for some
of these receptors may potentially affect SSRI action. To
date, there are data suggesting the plausible involvement of
at least seven specific 5-HT receptors in mediating SSRI
effects.
One class of 5-HT receptors (including 5-HT1a and 5-
HT1b) interacts primarily with inhibitory G-proteins to
decrease adenylyl cyclase (AC) activity. The 5-HT1a
receptor has been implicated in many SSRI effects (Dhaenen
2001; Bourin et al 2002; Blier and Ward 2003; Monaca et
al 2003). For example, blockade of 5-HT1a with antagonists
or the use of 5-HT1a knockout mice prevents the effect of
SSRIs on paradoxical sleep (Monaca et al 2003). Blockade
of this receptor also can augment antidepressant response
to SSRIs (Artigas et al 2001). Moreover, a 5-HT1a
polymorphism (C-1019G) has recently been associated with
vulnerability to major depression (Lemonde et al 2003). The
5-HT1b receptor has also been associated with irritability,
aggression, impulsivity, and possibly mood disorders
(Sanders et al 2002). In knockout mice lacking 5-HT1b,
some effects of SSRIs are abolished (Monaca et al 2003),
and 5-HT1b antagonists can also attenuate some SSRI
effects (Millan et al 2003). Polymorphisms in the gene for
5-HT1b, including a common A(-161)T SNP in the promoter
region, have been preliminarily associated with several
psychiatric phenotypes, including suicide (Hawi et al 2002;
Sanders et al 2002).
A second class of receptors includes 5-HT6 and 7. Each
of these receptors primarily interacts with stimulatory G-
proteins to increase adenylyl cyclase activity. Their function
has been less studied to date. The 5-HT6 receptor is involved
in neuronal serotonergic transmission and may have effects
on anxiety and mood (Yoshioka et al 1998). Further, a 5-
HT6 polymorphism (C267T) has been associated with
Parkinson’s disease (Messina et al 2002). Although an initial
study with 34 patients did not find an effect of a single 5-
HT6 polymorphism on treatment response (Wu et al 2001),
a more definitive study may be required to determine its
potential involvement in SSRI efficacy. The 5-HT7 receptor
is involved in hippocampal function (Gill et al 2002), and
has been implicated in the regulation of the glucocorticoid
receptor (Laplante et al 2002).
5-HT2a and 5-HT2c receptors primarily act at G-proteins
associated with phospholipase C (PLC). The 5-HT2a
receptor may play a role in SSRI response (Bonhomme and
Esposito 1998). In fact, antagonism at 5-HT2a can augment
the efficacy of SSRIs (Marek et al 2003), and response to
SSRI treatment has been associated with normalization of
5-HT2a receptor binding (Messa et al 2003). Consistent with
these findings, polymorphisms in the 5-HT2a gene (eg, G-
1438A and C102T) may be associated with vulnerability to
depression and suicide (Enoch et al 1999; Du et al 2000;
Arias et al 2001; Du et al 2001; Holmes et al 2003), although
this association has not been replicated in all studies (Bondy
et al 2000; Minov et al 2001). Further, a 5-HT2a poly-
morphism (G-1438A) may be associated with the response
to SSRIs in several populations (Cusin et al 2002; Sato et al
2002; Sugie et al 2003). A recent study in elderly depressed
subjects suggested that a 5-HT2a polymorphism (C102T)
may also be associated with sensitivity to the adverse effects
of mirtazapine, but was without influence on SSRI adverse
effects (Murphy GM et al 2003b).
SSRIs also affect the function of the 5-HT2c receptor
(Bristow et al 2000), with some adverse effects potentially
mediated by 5-HT2c. For example, the acute increases in
anxiety reported with SSRIs may be attenuated with 5-HT2c
antagonists, as assessed in animal models (Dekeyne et al
2000; Bagdy et al 2001). The 5-HT3 receptor, which is an
ionophore, may also be involved in mood disorders (Niesler
et al 2001) and sensitivity to some SSRI effects (Redrobe
and Bourin 1997). For example, 5-HT3 antagonists can
decrease SSRI-induced nausea (Wilde and Markham 1996).
G-proteins
Other than for the 5-HT3 receptor, most of the downstream
effects of 5-HT are mediated by G-proteins (Raymond et al
2001). There are 16 genes for G-protein α subunits, 5 for β,
and 12 for γ (Downes and Gautam 1999). In general, the αs
family activates adenylyl cyclases, the αi family inhibits
adenylyl cyclases, and the αq family activates phospholipase
C isozymes. The βγ complex modulates the activity of the
G protein α subunit. Many of these subunits are expressed
within the brain (Downes and Gautam 1999).
The αs subunit, which mediates many of the effects of
5-HT6 and 5-HT7 receptors, has a polymorphism in exon 5Neuropsychiatric Disease and Treatment 2005:1(1) 22
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that has been associated with major depression (Zill et al
2002). As this subunit is expressed in many areas of the
body, this polymorphism has also been associated with other
disorders including hypertension, which may be comorbid
with major depression (Jia et al 1999; Abe et al 2002). The
expression of αs is increased by SSRI treatment (Lesch et
al 1992). Polymorphisms in the G protein β3 subunit, which
is expressed in the brain, have also been associated with
both depression and cardiovascular disease (Bondy et al
2002; Zill et al 2002; Nurnberger et al 2003). Moreover,
preliminary evidence supports a role for this polymorphism
(C825T) in response to antidepressant treatment (Zill et al
2002; Serretti et al 2003), including SSRIs. The αi subunits,
which mediate the effects of 5-HT1 receptors, have several
isoforms expressed in the brain (Downes and Gautam 1999)
and have been implicated in antidepressant response in
mouse models (Galeotti et al 2002).
Adenylyl cyclases, protein
kinases, phospholipases, and
phosphodiesterases
Both the αs and αi G protein subunits directly affect the
function of adenylyl cyclase (AC), resulting in either
increased or decreased cyclic adenosine monophosphate
(cAMP), respectively. There are at least 9 genes encoding 9
different AC enzymes. Most are expressed in the brain,
although subtypes 1, 2, 6, 8, and 9 are more predominantly
so (Defer et al 2000). Antidepressant treatment, including
SSRIs, has been associated with increased transcription of
AC1 (Jensen et al 2000). 5-HT1a activation decreases
activity of neuronal AC2 (Albert et al 1999), and mice
lacking AC8 exhibit altered stress-induced anxiety (Schaefer
et al 2000). Each of these varied findings hints at a role for
various AC isozymes in mediating the antidepressant effects
of SSRIs. Initial studies of AC7 and AC9 polymorphisms
have been performed, although these particular isoforms
did not demonstrate an association with depression
(Hellevuo et al 1997; Toyota et al 2002).
Adenylyl cyclase activity increases cAMP, which then
binds to PKA. PKA is a tetramer containing two regulatory
(R) subunits and two catalytic (C) subunits. Type II PKA is
predominantly expressed in the brain. Activation by cAMP
results in dissociation of the R and C subunits, allowing the
C subunit to phosphorylate multiple substrates – including
but not limited to the b-adrenergic receptor, the nicotinic
acetylcholine receptor, sodium and calcium channels, N-
methyl-D-aspartate (NMDA) receptor subunits, tyrosine
hydroxylase, neurofilaments, microtubule associated protein
2 (MAP2), synapsin I, rabphilin, GABA A receptor subunits,
SERT, and cAMP response element-binding protein (CREB)
(Nibuya et al 1996; Wischmeyer and Karschin 1996).
Abnormalities in PKA/CREB signaling have been associated
with mood disorders (Shelton et al 1996; Rahman et al 1997;
Chang et al 2003; Kohen et al 2003). For example, an
increase in phosphorylated CREB was noted in the
postmortem prefrontal cortexes of depressed victims of
suicide, but only in antidepressant-free subjects (Odagaki
et al 2001). Decreased CREB was observed, however, in
the temporal cortexes of subjects who had had major
depression, but only in antidepressant-free subjects
(Dowlatshahi et al 1998). Although the relationship between
PKA/CREB and major depression may be complex,
antidepressants normalized the CREB measures in both
studies.
Stimulated by these observations, several theories of
SSRI action have hypothesized a primary role for CREB
phosphorylation by PKA (Duman et al 1997; Shelton 2000),
as reviewed below. However, other phosphorylation events
may also be important. For example, in neurons, PKA RIIb
(regulatory subunit IIb) mediates association with
membranes, where PKA is coupled with MAP2. As noted
above, PKA can phosphorylate MAP2, decreasing micro-
tubule assembly, and potentially affecting dendritic and
synaptic growth (Nestler et al 1989; Miyamoto et al 1997).
Chronic SSRI treatment is capable of increasing PKA
in select brain areas (Perez et al 1991; Rausch, Gillespie, et
al 2002) while decreasing PKA in others (Rosin et al 1995).
Additionally, SSRI treatment can result in a translocation
of PKA into various intracellular compartments, potentially
corresponding to its eventual antidepressant effect (Mori et
al 1998). Although abnormalities in PKA activation have
been associated with differences in response to
noradrenergic antidepressants (Gurguis et al 1999), a
systematic study of polymorphisms affecting PKA has not
yet been performed. Given the widespread expression of
PKA subunits, polymorphisms that drastically affect
function may be expected to have widespread deleterious
effects (Stergiopoulos and Stratakis 2003).
The cAMP produced by adenylyl cyclase is recycled by
phosphodiesterases (PDEs). A limited number of the
multiple PDE isoforms are expressed in the brain. In
particular, PDE4 exists in brain regions involved in mood
(Cherry and Davis 1999). Interestingly, PDE4 inhibitors
such as rolipram have antidepressant effects. AntidepressantsNeuropsychiatric Disease and Treatment 2005:1(1) 23
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affect transcription of PDE4 (Ye et al 2000; Miro et al 2002;
Zhao et al 2003), and PDE4D may mediate some anti-
depressant effects of rolipram in animal models (Zhang
et al 2002).
As noted, CREB is directly activated by PKA. It is also
notable that the chromosomal region containing CREB has
been linked with depression (Zubenko et al 2002). CREB is
a member of the leucine zipper family of transcription
factors, activating or repressing multiple genes with the
cAMP response element (CRE) promoter (Yamamoto et al
1988). Chronic antidepressant treatment, including SSRIs,
can increase CREB mRNA in some brain areas (Nibuya et
al 1996), and alterations in CREB activity have been
associated with antidepressant effects. For example,
increased peripheral CREB phosphorylation at two weeks
was correlated with antidepressant response (Koch et al
2002). Conversely, increased CREB expression in the
nucleus accumbens may adversely affect motivated behavior
(Pliakas et al 2001; Newton et al 2002). CREB also increases
BCL-2 (B-cell leukemia-2) expression (Riccio et al 1999)
and is necessary for the increased brain-derived neurotrophic
factor (BDNF). Both effects potentially influence neuronal
survival (Conti et al 2002). Many genes have CRE in their
promoter regions including nerve growth factor1A,
corticotropin-releasing hormone, BDNF, and glucocorticoid
and mineralocorticoid receptors.
Another protein that has recently been implicated in
mediating the effects of SSRIs through PKA and other
transduction pathways is the dopamine and cAMP regulated
phosphoprotein (DARPP-32). DARPP-32 is an inhibitor of
protein phosphatase-1 (PP1). Inhibiting protein phosphatase
activity may amplify the effects of PKA. The efficacy of
fluoxetine, an SSRI, is diminished in mice that are lacking
DARPP-32 (Svenningsson et al 2002). Other protein
phosphatases that may affect SSRI response will be reviewed
below.
In addition to these effects immediately downstream
from adenylyl cyclase activity, 5-HT activates PLC by 5-
HT2 receptor-associated G-proteins. There are multiple
isoforms for PLC. PLC, via creation of diacylglyceral, then
activates PKC. Both PKC and PLC have been associated
with depression (Shelton 2000), and there is evidence for
PLCs involvement in mediating some SSRI effects
(Rasenick et al 1996).
Polymorphisms in PLCγ1, such as an intronic
dinucleotide repeat, have been associated with bipolar
disorder and response to lithium treatment (Turecki et al
1998; Lovlie et al 2001). Additionally, antidepressant
treatment can decrease the expression of PLCβ in animal
models (Dwivedi et al 2002). 5-HT2-coupled G-proteins
also activate phospholipase A2, releasing arachidonic acid
from phospholipids. Via this pathway, SSRIs have been
shown to increase the activity of phospholipase A2 (Qu et
al 2003a, 2003b), and an intronic trinucleotide repeat
polymorphism in phospholipase A2 may be associated
with mood disorders (Meira-Lima et al 2003; Papadimitriou
et al 2003).
PKC has at least 12 isoforms (Way et al 2000). In the
brain, the isoforms α, β1,β2, γ, ε, δ, and ζ are expressed,
although γ is most predominantly specific to the central
nervous system (Saito and Shirai 2002). On activation, PKC
translocates from the membrane to specific compartments
such as the nucleus, cytoskeleton, and postsynaptic densities.
Subsequent PKC substrates include vinculin, annexins,
neuromodulin, and myrisoylated alanine-rich C-kinase
substrate (MARCKS). PKC also desensitizes 5-HT2A
receptors (Rahimian and Hrdina 1995) and downregulates
SERT (Ramamoorthy et al 1998). Other neuronal functions
include modulation of ion channels, norepinephrine
transporters, and long-term potentiation (Saito and Shirai
2002). Interestingly, chronic treatment with SSRIs decreases
PKC function in the cortex and hippocampus (Mann et al
1995).
Another effect of PLC is to increase the metabolism of
phosphoinositol via activation of inositol phosphatase, with
subsequent effects on cytoplasmic calcium levels. In turn,
the increased calcium can activate CAMKII, which is the
most abundant protein kinase in the brain and is particularly
enriched at synaptic sites. Polymorphisms in some CAMKII
isoforms have been demonstrated (Gloyn et al 2002), and
both the α and β isoforms for CAMKII are expressed in the
brain (Chang et al 2001). At the cellular level, CAMKII
activation is associated with increased neurotransmitter
release and long-term potentiation. For example,
phosphorylation of the N-type calcium channel by CAMKII
affects its interaction with SNARE (soluble N-
ethylmaleimide-sensitive factor attachment
 protein receptor)
proteins in influencing neurotransmitter release (Yokoyama
et al 1997). Increased neurotransmitter release may also be
affected by phosphorylation of synaptotagmin, a crucial
element of calcium-induced exocytosis. Chronic
antidepressant treatment increases CAMKII in selective
brain areas (Popoli et al 1995; Pilc et al 1999; Consogno et
al 2001; Celano et al 2003).Neuropsychiatric Disease and Treatment 2005:1(1) 24
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Protein phosphatases
Multiple protein phosphatases (PPs) are present in the brain
to dephosphorylate proteins, reversing the effect of kinases
(Price and Mumbly 1999). One example is PP1 which has
at least three isoforms expressed in the brain (da Cruz e
Silva et al 1995). Interaction with spinophilin results in
localization of PP1 to the dendritic spines, while interaction
with tau bridges PP1 to microtubules (Allen et al 1997). In
dendritic spines, PP1 can dephosphorylate CAMKII and
glutamate receptors (Kennedy 1998), and PP1 activity may
be necessary for effects of 5-HT in acutely affecting
prefrontal cortical neuronal activity (Cai et al 2002). There
are also genes for several associated regulatory proteins.
For example, DARRP-32, whose involvement in potentially
affecting SSRI response was discussed above, is a regulator
of PP1 (Svenningsson et al 2002).
A second phosphatase, PP2A, exists as a heterotrimer,
with a catalytic, regulatory, and scaffolding subunit. Both
the catalytic and scaffolding subunits exist throughout the
brain, and there are several region-specific regulatory
subunits (Stack et al 1998). In addition to other activities,
PP2A can exist in close relationship with the SERT protein
and is involved in regulating SERT’s activity (Bauman et al
2000). PP2B, also known as calcineurin, exists throughout
the brain but is particularly enriched in hippocampal
dendritic spines. It is activated by calcium/calmodulin (Klee
et al 1998). Through the calcium/calmodulin/PP2B pathway,
5-HT2 receptor activation can inhibit calcium channels in
the prefrontal cortex (Day et al 2002). However, along with
several other PPs in the brain (PP2C, PP4, PP5, PP6) (Cohen
1997), a function in potentially modulating SSRI-induced
intracellular transduction remains to be determined.
Regulatory and scaffolding
proteins
Notably many of these intracellular transduction pathways
interact in complex ways, depending on the intracellular
compartment and association of other regulatory proteins
(Sim and Scott 1999; Robinson-White and Stratakis 2002).
In addition to the proteins discussed above, others may
indirectly play roles. There are multiple regulators of G-
protein signaling (RGS) (Chidiac and Roy 2003) that directly
modulate G-protein function; multiple receptors for
activated PKC (RACKs) that may be important for
translocation of PKC to specific intracellular locations; and
multiple anchoring proteins that can regulate the location,
function, and interaction of various protein kinases (Scott
1997; Bayer and Schulman 2001). As just one example, A-
kinase anchoring protein 79/150 (AKAP79/150) is an
anchoring protein that interacts with PKA, PKC, and PP2B.
It can recruit these three enzymes to glutamate receptors in
the dendritic spine via an interaction with membrane-
associated guanylate kinase scaffold proteins. Conversely,
the activity of AKAP79/150 is regulated by PKC and
calmodulin (Gomez et al 2002).
To briefly review, there is accumulating evidence in
support of several protein kinases, protein phosphatases, and
other related second messengers in mediating the effects of
SSRIs. Importantly, there is also accumulating initial
evidence in support of proximal, intracellular pathway
polymorphisms affecting SSRI efficacy. However, for most
of these proteins, the association of genetic variation and
variable response to SSRIs has yet to be fully investigated.
Moreover, chronic administration of SSRIs can also
affect various systems that are downstream from these
intracellular transduction pathways. Several of these systems
have been implicated in depression, as briefly outlined in
the next sections, and may offer biologically plausible
candidates for association analyses of SSRI response.
Hypothalamic-pituitary-adrenal
axis
Stress and dysregulation of the hypothalamic-pituitary-
adrenal (HPA) axis has long been associated with depression
(Gold et al 1988; Gold and Chrousos 2002; Strohle and
Holsboer 2003), and CRH antagonists may have
antidepressant properties (Kunzel et al 2003). Because
antidepressants can increase glucocorticoid receptor (GR)
expression and potentially normalize the HPA axis, this has
been proposed as one mechanism of action (Barden et al
1995; Holsboer 2000; Herr et al 2003). Antidepressants also
can alter the synthesis and release of CRH, thereby
normalizing the HPA axis (Brady et al 1991; Torres et al
1998). Consistent with this, polymorphisms in the CRH gene
that affect cortisol secretion (Rosmond et al 2001) have been
described (Gonzalez-Gay et al 2003), and may be associated
with major depression (Claes et al 2003) as assessed using
haplotype analyses.
An initial investigation of a CRH receptor 2 poly-
morphism (G1047A) also hinted at a possible role in mood
disorders (Villafuerte et al 2002). Polymorphisms in GR
have been associated with obesity (Di Blasio et al 2003),
sensitivity to dexamethasone challenges (Huizenga et al
1998), and possibly to abnormal responses to stress (DeRijkNeuropsychiatric Disease and Treatment 2005:1(1) 25
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et al 2002). Of note, mineralocorticoid receptor (MR) gene
expression is also affected by chronic antidepressant
treatment in rats (Brady et al 1991), and MR function has
also been linked to the pathophysiology of depression
(Young et al 2003).
Brain-derived neurotrophic factor
and neurogenesis
SSRIs can increase neurogenesis in the hippocampus
(Malberg et al 2000; Santarelli et al 2003), and hippocampal
neurogenesis has been implicated as a requirement for the
behavioral effects of antidepressants (Santarelli et al 2003).
Increased BDNF, a neurotropin, may mediate this
antidepressant effect of SSRIs (Nibuya et al 1995; Duman
et al 1997; Altar 1999; Duman et al 1999; Shirayama et al
2002). BDNF may also, in turn, regulate the expression of
SERT, an affect that can be modulated by the 5-HTTLPR
(Mossner et al 2000). A polymorphism in BDNF has been
preliminarily associated with bipolar disorder (Neves-
Pereira et al 2002), although this was not found in a Chinese
population of subjects with mood disorders (Hong et al
2003).
The receptor for BDNF is trkB (troponin/receptor kinase
B), which is affected by antidepressant treatment, including
SSRIs, and appears to be necessary for antidepressant effects
(Rumajogee et al 2002; Saarelainen et al 2003). Moreover,
antidepressants not only increase the expression of BDNF
and trkB, but also neurotrophin-3, (Nibuya et al 1995; Smith
et al 1995; Nibuya et al 1996; Duman et al 1997). Of note,
transcription for each of these three is increased by CREB
(Duman et al 1997). The cAMP/PKA/CREB mediated
effects may therefore be ultimately mediated by BDNF
acting at the trkB receptor (Galter and Unsicker 2000).
Several intracellular kinases transduce BDNF effects.
For example, there are mitogen-activated protein (MAP)
kinase cascades, which also involve extracellular signal-
regulated protein kinase (ERK) (Gould and Manji 2002;
Manji and Chen 2002). BDNF infusion increases ERK
phosphorylation and immediate early genes (Shirayama
et al 2002). Inhibition of mitogen and extracellular signal-
regulated protein kinase (MEK), which mediates the
BNDF-induced phosphorylation of ERK, prevents the anti-
depressant effects of BDNF in animal models (Shirayama
et al 2002). Both MAP kinase and ERK have been implicated
in mediating the 5-HT1A effect of inhibiting caspase-3 and
apoptosis (Adayev et al 2003). Abnormalities in ERK1 and
ERK2 have been noted in animal models of depression (Feng
et al 2003), and decreased neuronal ERK expression is seen
in victims of suicide (Dwivedi et al 2001). Other potential
downstream effector molecules for BDNF that may enhance
neuronal survival, augment neuroplasticity, or decrease
apoptosis include Bcl-2 and glycogen synthase kinase 3
(Manji et al 2001; Gould and Manji 2002; Manji and
Chen 2002).
Additional neurotransmitters
There are multiple neurotransmitter systems that interact in
complex ways. Further, many of these neurotransmitter
systems share the same intracellular transduction pathways.
The cholinergic, noradrenergic, and dopaminergic systems
may all be dysregulated in depression (Leonard 1996; Chau
et al 1999; Iversen 2000; Schatzberg et al 2002; Shytle et al
2002; Shaffery et al 2003). In fact, various polymorphisms
in the norepinephrine and dopamine systems have been
associated with mood disorders (Jonsson et al 1998; Mason
et al 1999; Mitchell et al 2000; Suzuki et al 2001; Massat et
al 2002; Ni et al 2002; Ranade et al 2002; Rosmond et al
2002; Urwin et al 2002; Jonsson et al 2003; Ueno 2003). A
polymorphism in the muscarinic-2 receptor has also been
associated with depression (Comings et al 2002).
Preliminary studies do not support roles for select
polymorphisms in D2 and D4 dopamine receptors in
affecting treatment response (Serretti et al 2001b). However,
polymorphisms in other monaminergic and cholinergic
receptors may interact with SSRI efficacy. For example,
catachol-O-methyltransferase primarily metabolizes
dopamine and norepinephrine and has a polymorphism that
has been associated with poor response to SSRIs (Catalano
2001).
There are abnormalities in the glutamatergic system in
depression (Skolnick 2002; Sanacora et al 2003). Moreover,
enhancement of α-amino-3-hydroxy-5-methyl-4-isoxazole
proprionic acid (AMPA) receptor activity and decreased
NMDA receptor activity may potentiate the antidepressant
effect of SSRIs (Rogoz et al 2002; Li et al 2003). Of the 5
genes coding for NMDA receptor subunits (NR1 and NR2A-
NR2D) and 4 for AMPA receptors (GluR1-GluR4), a
polymorphism in the NR1 gene has preliminarily been
associated with mood disorders (Mundo et al 2003).
The nitric oxide system also interacts with 5-HT in
moderating behavior (McLeod et al 2001; Chiavegatto and
Nelson 2003). Interestingly, a polymorphism for neuronal
nitric oxide synthetase (C29T) has been preliminarily
associated with depression and response to SSRIs (Yu, Chen,Neuropsychiatric Disease and Treatment 2005:1(1) 26
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Wang, et al 2003). Vasopressin (Keck et al 2003),
neuropeptide Y (Caberlotto et al 1998; Pandey et al 2003),
and dynorphin (Chen et al 2002; Newton et al 2002) may
also play roles.
Ion channels and synaptic
transmission
As noted above, 5-HT transmission and subsequent
intracellular transduction cascades can also effect ion
channels, thereby affecting neuronal excitability and
neurotransmitter release (Nunoki et al 1989; Blier and de
Montigny 1994; Levitan 1994; Wischmeyer and Karschin
1996; Fairchild et al 2003). One example is the G-protein-
gated inwardly rectifying potassium channel (GIRK), which
regulates membrane excitability. At least three subunits for
GIRK are native to hippocampal neurons, Kir3.1, Kir3.2A,
and Kir3.2C, and these may mediate some 5-HT1A
responses (Fairchild et al 2003).
SSRIs can also decrease synaptic function in select areas
by influencing calcium channels. For example, inhibition
of P/Q-type calcium channels in cerebrocortical neurons
by fluoxetine can be mediated by a PKC pathway, resulting
in decreased neurotransmission (Wang et al 2003).
Consistent with these observations, blockade of calcium
channels using verapamil or diltiazem can attenuate the
effectiveness of SSRIs in animal models of depression
(Srivastava and Nath 2000).
Other molecules affecting synaptic transmission have
been similarly implicated in the downstream effects of
antidepressants. For example Pyk2 (proline-rich tyrosine
kinase 2) is a tyrosine kinase that can modify the activity of
NMDA receptors and voltage-gated potassium channels in
the lateral septum, enhancing synaptic transmission and
long-term potentiation (Sheehan et al 2003). Other potential
moderators of antidepressant response include
apolipoprotein E (ApoE) and various immunologic
cytokines that may affect depression (Song et al 1998;
Alvarez et al 2002; Anisman et al 2002; Anisman and Merali
2002; Murphy GM et al 2003a; Yu, Chen, Hong, et al 2003).
Unanticipated candidates based on
microarray and genomic screening
A recent microarray study examining whole frontal cortex
(Landgrebe et al 2002) has identified 16 genes that were
influenced by SSRI treatment in mice – all were down-
regulated. Only one related to signal transduction, six were
involved in metabolism, two in cell-cycle regulation, and
one was a homeobox transcription factor. An alternative
approach has been to examine the effect of chronic stress in
tree shrews, using a subtractive hippocampal cDNA library.
Chronic stress decreased the expression of neural growth
factor, membrane glycoprotein 6a, CDC-like kinase 1, and
G-protein subunit αq. Treatment with clomipramine
mitigated these transcriptome changes (Alfonso et al 2004).
If confirmed, the findings from this nascent technology may
eventually provide unsuspected, novel candidate genes for
association analyses.
Summary
A number of neurotransmitter and neuromodulatory systems
are associated both with mood disorders such as MDD and
response to antidepressant treatment. Each of these systems
offers a biologically plausible target for selection of
candidate genes affecting SSRI response. Empirically
delineating the genetic polymorphisms in these various
systems that, in fact, influence SSRI response will be an
important goal for the next generation of studies examining
treatment outcome.
Given that many of the proteins, such as adenylyl cyclase,
Gi subunits, and protein phosphatases have multiple
isoforms, selecting specific isoforms for genetic analysis
may require first determining which isoforms are involved
in neuronal SSRI-influenced pathways. Further, once a
specific gene is chosen for analysis, the next step requires
selecting which polymorphism(s) within the gene to study.
Because genes often have multiple polymorphisms, it is
unfeasible to assess them all. Conversely, studies that test
only a single polymorphism may erroneously conclude that
a gene is not involved in SSRI response, but miss testing an
important functional polymorphism in that gene. Often, it
is ideal to choose polymorphisms with known functional
affects. It may be useful to choose polymorphisms that have
had previously demonstrated associations with other
phenotypes of interest such as MDD. Ultimately, selecting
a subset of several polymorphisms within a gene for
haplotype analysis may provide improved power over
choosing only a single polymorphism for study (Hoehe et
al 2003). This is of particular relevance for interpreting those
studies that report a lack of association for single
polymorphisms. If the complete gene including its regulatory
regions is not examined, functionally important genetic
differences may be missed and lack of importance for a gene
erroneously inferred. This is a critical shortcoming in many
recent papers reporting “negative” findings.Neuropsychiatric Disease and Treatment 2005:1(1) 27
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Discussion
As individual polymorphisms are likely to have small effect
sizes, identifying multiple genes may be necessary to
generate a complete picture of genetic variability and
responsiveness to SSRIs. By identifying likely targets based
on current knowledge regarding the mechanisms of SSRI
action, a variety of potential candidates have been culled.
This review has attempted to suggest multiple candidate
genes based on known and putative mechanisms of SSRI
action. Notably, the number of targeted genes represents
less than 0.5% of the genome. With current high-throughput
methodologies for assessing polymorphisms, examining this
large but significantly limited number of genes is feasible
(Cowan et al 2002).
However, studies of variable antidepressant response are
affected by several methodologic issues that are inherent in
antidepressant trials. There are fundamental considerations
regarding the phenotypic definition of antidepressant
response (Nierenberg 2003). For example, although
depression is a complex and polythetic disorder (Kendler et
al 1992; Kendell 2001), it is often treated as a single entity.
Similarly, defining response is problematic (Nierenberg and
DeCecco 2001). Response can be quantified as the rate of
response or the magnitude of response. It can also be
qualitatively defined as achieving a predetermined level of
symptomatology. Different genes may specifically affect
different aspects and/or subtypes of depression, or they
may specifically affect different elements of response. That
is, there may be a number of “mood disorders”, or even
subtypes of “major depression”, that may respond
differently to SSRIs. Additionally, some genetic variation
may be associated with different types of side effects and
different rates of developing tolerance to side effects, rather
than antidepressant response itself (Murphy GM et al
2003b). Unfortunately, there is extremely little data to date
regarding the association of polymorphisms with different
measures of response, tolerance to SSRIs, or different side
effects of SSRIs.
Moreover, determining true drug responders is also
complicated by partial or non-adherence to the medication
(Thompson et al 2000). In addition to variable adherence,
the concentration of SSRIs can be influenced by dosage
and environmental factors. The effect of some poly-
morphisms may be evident at low SSRI concentrations but
not at higher concentrations, or vice versa. For example,
we have noted that 5-HTTLPR is associated with variable
response to paroxetine in the first few weeks, but that
response to the SSRI did not differ after several weeks
(Pollock et al 2000). Given that paroxetine can inhibit its
own metabolism, we observed that paroxetine levels
increased after several weeks in elderly individuals, to
concentrations potentially sufficient for noradrenergic
involvement (Gilmor et al 2002). This is of interest given
that 5-HTTLPR was not associated with response to a
noradrenergic reuptake inhibitor (Pollock et al 2000). For
this reason, as well as statistical reasons, accounting for
adherence and SSRI exposure may be essential in association
studies of treatment response (Judson 2003; Selinger-
Leneman et al 2003). Accounting for adherence and SSRI
exposure in these types of studies has been extremely limited
to date.
There is also the ever-escalating problem of placebo
response rates in clinical trials (Walsh et al 2002). This is
complicated by the aggregation of potential subtypes of
depression in clinical studies and the relative exclusion of
other subtypes, with some subtypes possibly having variable
drug responsiveness (Parker et al 2002). If these confounding
elements are not accounted for, erroneous conclusions are
possible.
Population stratification is another concern. Methods
such as genomic control and structured association may be
used to correct for population substructuring (Devlin et al
2001). However, ethnic and cultural difference may
confound results in other ways (Balant and Balant-Gorgia
2000). For example, adherence, social background, and
ethnic differences may all interact to affect treatment
response (Lotrich et al 2003), and the frequency of many
polymorphisms varies with ancestry. Given these methods
are now available for accounting for population stratification
(eg, Devlin et al 2001), they should be included in these
types of association studies.
There are also statistical issues pertaining to testing
multiple polymorphisms. More sophisticated modeling may
be necessary to accurately determine appropriate
significance levels when testing multiple associations (Lucek
et al 1998). For example, one suggested approach is to
control for the false discovery rate (FDR), rather than focus
on controlling the rate of false positives or false negatives
(van den Oord and Sullivan 2003). That is, rather than
stringently protecting against a single false rejection of a
null hypothesis, FDR limits the percentage of false
rejections, providing improved power when testing many
likely candidate hypotheses (Devlin et al 2003). Further,
there are additional methodological issues such as
appropriate sample sizes (McCarthy and Hilfiker 2000) andNeuropsychiatric Disease and Treatment 2005:1(1) 28
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genotyping procedures (Schulze et al 2003) that require
consideration. Many studies reviewed above have
insufficient sample sizes to meaningfully interpret
“negative” findings.
Future studies carefully attending to these issues will
likely yield a useful picture regarding the genetic variation
affecting SSRI response. Candidate genes for these
association analyses, selected from known and putative
pathways of SSRI action, include polymorphisms affecting
the serotonin transporter, serotonin receptors, intracellular
transduction, the HPA axis, BDNF and neurogenesis, and
other neurotransmitter systems. A complete picture of
genetic variation will involve determining the relative role
of multiple polymorphisms, their effect sizes, their
interactions, their interactions with pharmacokinetic
differences, and their relationship with environmental factors
that influence treatment outcome.
As noted above, there are many methodological issues
that require close consideration. There is wide variation
among studies in attention to these issues (eg, careful
definition of the study population in terms of ethnicity,
demographics, environment, diagnoses, and comorbidities;
careful definition of types of response; controlling for
genetic variability in placebo response; controlling for
differences in medication exposure; appropriate statistical
analyses and attention to population substructure; and
appropriate selection of a set of polymorphisms across the
candidate gene).
This is a nascent, but quickly maturing field. To date,
studies that have carefully attended to these concerns are
very limited. Nonetheless, it is reasonable to predict that
the goal of genetically determining which individual patients
will benefit from SSRIs and which should be targeted for
alternative therapies may be attainable in the near future.
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